| Motesanib |
ENSG00000088970.11 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000088970.11 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000130600.11 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000131484.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000167912.5 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000170846.11 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000170846.11 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000174171.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000175701.6 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000177337.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000177640.11 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000179523.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000179743.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000179818.9 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000179935.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000180769.4 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000181097.5 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000181798.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000181798.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000182165.13 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000182873.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000184068.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000185186.4 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000185203.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000185433.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000185837.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000185837.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000186369.5 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000188365.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000189223.9 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000196295.7 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000196421.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000196553.9 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000196553.9 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000196972.6 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000197332.7 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000197813.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000197989.9 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000203362.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000203497.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000203506.3 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000203588.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000203601.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000203620.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000203635.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000203739.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000203865.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000203875.6 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000203999.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000204044.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000204055.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000204055.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000204625.6 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000204934.6 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000204934.6 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000205037.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000205041.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000205266.5 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000205488.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000205885.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000205959.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000206140.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000206176.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000206195.6 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000211683.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000212552.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000212552.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000212694.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000212978.5 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000213994.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000214145.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000214614.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000214725.3 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000214773.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000214870.4 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000214922.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000215039.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000215190.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000215394.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000215458.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000215863.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000218510.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000218510.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000222041.6 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000223396.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000223414.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000223478.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000223511.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000223528.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000223546.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000223561.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000223573.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000223576.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000223579.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000223598.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000223642.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000223652.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000223695.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000223697.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000223704.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000223734.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000223734.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000223745.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000223745.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000223745.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000223759.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000223774.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000223829.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000223842.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000223884.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000223935.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000224020.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000224063.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000224079.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000224100.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000224100.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000224167.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000224259.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000224441.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000224481.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000224505.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000224509.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000224514.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000224533.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000224536.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000224623.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000224687.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000224687.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000224699.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000224707.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000224729.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000224745.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000224745.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000224764.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000224790.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000224843.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000224855.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000224888.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000224899.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000224945.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000224945.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000224961.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000224969.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000224972.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000224973.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000224985.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000225084.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000225092.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000225146.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000225146.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000225177.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000225195.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000225210.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000225213.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000225278.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000225278.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000225300.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000225300.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000225300.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000225335.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000225353.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000225361.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000225407.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000225439.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000225470.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000225493.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000225506.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000225506.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000225555.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000225578.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000225578.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000225579.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000225595.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000225643.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000225643.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000225643.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000225675.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000225764.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000225767.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000225783.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000225791.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000225798.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000225798.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000225839.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000225913.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000225969.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000225975.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000225981.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000225981.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000226009.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000226009.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000226029.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000226067.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000226237.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000226287.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000226302.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000226310.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000226334.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000226363.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000226375.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000226386.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000226471.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000226609.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000226688.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000226696.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000226862.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000226876.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000226876.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000226904.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000227014.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000227047.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227070.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000227110.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000227197.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000227210.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000227215.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227220.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000227256.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000227256.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000227258.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000227279.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000227354.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227373.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000227375.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000227375.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000227388.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000227431.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000227431.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000227477.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000227479.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000227492.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000227492.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227533.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227579.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227603.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000227606.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000227627.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227634.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227637.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000227640.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227676.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000227704.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000227885.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000227896.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000228005.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000228043.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000228084.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228107.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228113.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000228124.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228126.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000228192.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000228237.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228265.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000228294.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228315.7 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228317.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000228352.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000228393.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228393.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228412.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000228436.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000228444.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000228486.5 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000228527.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000228544.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228554.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000228598.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228613.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000228634.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000228661.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228661.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000228677.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228686.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000228701.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228718.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228719.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228734.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228737.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000228775.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228784.3 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000228801.5 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000228802.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000228809.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228812.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000228839.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228852.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000228889.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000228939.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000229021.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000229021.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000229065.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000229124.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000229180.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000229261.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000229263.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000229263.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000229348.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000229444.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000229463.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000229512.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000229582.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000229645.4 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000229688.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000229688.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000229728.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000229780.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000229832.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000229839.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000229955.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000229990.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000230024.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230054.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000230054.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000230054.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230061.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000230061.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230074.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000230084.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000230133.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230269.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000230289.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000230289.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230310.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000230310.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000230310.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000230415.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000230424.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000230424.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000230530.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000230530.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000230550.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230606.6 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000230612.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000230613.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000230648.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000230658.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230663.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230679.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000230732.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230751.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230806.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000230815.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000230896.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000230922.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000230925.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000230939.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000230971.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000231025.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000231057.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231081.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231102.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000231104.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231113.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231154.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231154.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000231187.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000231249.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231312.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000231312.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000231365.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000231401.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000231439.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231473.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000231483.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000231507.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231519.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000231521.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000231521.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231530.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000231551.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231551.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000231609.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231611.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231646.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231652.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000231704.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000231709.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231711.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231734.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231742.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000231760.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000231760.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231764.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231764.4 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000231789.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000231842.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000231871.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231889.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231999.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000231999.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000232006.4 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000232019.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000232019.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000232043.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000232046.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000232063.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000232063.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000232077.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000232082.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000232098.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000232098.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000232139.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000232160.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000232259.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000232274.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000232284.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000232336.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000232377.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000232455.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000232455.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000232527.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000232536.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000232586.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000232593.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000232593.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000232611.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000232633.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000232640.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000232693.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000232710.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000232712.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000232721.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000232732.5 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000232814.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000232876.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000232893.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000232973.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233013.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233077.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233086.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000233137.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000233144.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000233184.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233184.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000233203.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000233237.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233237.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000233246.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000233250.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000233360.4 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000233387.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233452.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000233478.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000233501.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000233509.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000233554.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000233611.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233613.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000233621.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000233621.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000233654.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000233661.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000233775.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000233783.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000233785.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233791.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233854.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000233895.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233901.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000233967.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000233975.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000234019.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000234050.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000234062.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000234134.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000234160.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000234206.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000234206.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000234210.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000234230.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000234232.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000234263.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000234264.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000234311.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000234327.3 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000234393.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000234478.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000234509.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000234509.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000234567.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000234608.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000234617.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000234617.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000234665.4 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000234676.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000234684.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000234684.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000234694.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000234694.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000234741.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000234753.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000234763.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000234772.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000234773.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000234773.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000234789.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000234793.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000234869.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000234900.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000234902.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000234912.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000234913.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000234917.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000234936.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000234978.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000234996.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000235027.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000235052.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000235092.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000235117.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235204.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000235236.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000235236.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000235262.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000235262.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000235271.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000235373.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235381.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235398.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235423.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000235426.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000235475.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000235522.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235522.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000235527.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235560.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000235703.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235706.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000235726.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000235770.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000235772.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000235806.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235823.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235831.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000235888.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000235910.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000235927.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000235999.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236088.5 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000236137.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000236140.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000236140.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000236144.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000236144.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236200.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236206.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000236266.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000236308.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000236333.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000236352.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236358.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236432.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000236463.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000236463.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000236463.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000236472.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000236494.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000236519.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236526.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000236528.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236546.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000236581.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000236601.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000236601.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000236643.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000236682.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000236682.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000236703.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000236711.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000236743.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236751.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236810.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000236810.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000236824.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000236830.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000236859.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000236869.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000236869.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000236896.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000236901.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000236924.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000236936.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000236943.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000236953.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000236986.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000236991.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000237021.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000237037.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000237128.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000237188.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000237253.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000237310.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000237328.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000237336.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000237343.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000237343.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000237356.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000237357.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000237429.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000237489.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000237491.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000237491.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000237502.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000237502.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000237513.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000237594.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000237594.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000237609.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000237685.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000237689.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000237738.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000237738.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000237798.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000237819.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000237836.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000237903.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000237945.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000237950.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000237975.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000237978.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000238005.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000238078.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000238160.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000238197.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000238261.5 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000238266.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000238280.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000238290.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000239415.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000239569.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000239608.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000239664.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000239705.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000239828.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000239906.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000239911.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000240050.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000240050.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000240086.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000240254.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000240350.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000240440.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000240440.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000240453.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000240541.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000240591.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000240758.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000240907.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000240990.5 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000241135.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000241219.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000241481.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000241520.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000241599.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000241770.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000241860.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000241886.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000242136.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000242258.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000242349.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000242391.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000242396.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000242474.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000242578.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000242808.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000243055.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000243187.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000243230.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000243230.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000243389.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000243479.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000243637.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000243766.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000243819.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000243849.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000243926.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000244479.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000244625.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000244757.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000244791.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000244879.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000244952.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000244998.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000245248.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000245293.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000245322.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000245322.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000245322.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000245498.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000245526.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000245534.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000245534.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000245534.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000245556.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000245648.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000245662.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000245849.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000245975.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000246090.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000246130.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000246174.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000246174.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000246263.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000246308.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000246334.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000246379.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000246528.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000246560.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000246582.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000246695.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000246740.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000246763.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000246792.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000246863.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000246863.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000246889.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000246982.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000247199.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000247199.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000247228.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000247271.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000247324.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000247324.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000247363.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000247372.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000247372.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000247400.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000247498.5 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000247556.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000247556.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000247679.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000247708.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000247735.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000247877.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000247925.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000247950.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000248019.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000248027.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000248100.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000248131.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000248161.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000248206.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000248206.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000248309.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000248356.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000248373.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000248468.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000248473.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000248476.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000248476.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000248508.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000248508.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000248514.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000248559.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000248671.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000248677.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000248693.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000249096.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000249216.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000249258.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000249258.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000249406.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000249451.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000249453.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000249456.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000249476.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000249502.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000249532.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000249637.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000249641.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000249700.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000249786.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000249846.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000249859.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000249870.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000249898.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000249916.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000249916.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000249984.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000250039.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000250075.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000250081.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000250116.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000250132.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000250132.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000250220.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000250220.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000250222.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000250326.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000250397.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000250490.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000250541.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000250608.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000250616.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000250616.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000250635.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000250714.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000250790.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000250790.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000250802.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000250820.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000250842.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000250900.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000250917.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000250988.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000251009.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000251026.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000251026.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000251136.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000251148.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000251179.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000251292.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000251298.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000251330.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000251361.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000251455.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000251460.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000251555.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000251556.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000251602.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000251603.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000251613.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000251615.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000251661.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000251661.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000251687.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253141.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253347.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253372.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253433.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253438.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000253475.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000253507.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253508.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253515.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000253552.3 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000253716.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253764.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000253773.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253784.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000253799.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000253878.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253893.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000253893.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000253930.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253948.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000253948.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000253972.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000253982.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000254028.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000254034.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000254042.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000254099.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000254143.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000254153.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000254153.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000254187.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000254204.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000254207.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000254207.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000254233.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000254275.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000254343.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000254353.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000254539.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000254560.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000254602.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000254604.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000254606.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000254631.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000254635.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000254662.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000254682.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000254687.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000254688.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000254691.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000254731.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000254731.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000254812.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000254826.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000254837.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000254855.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000254860.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000254879.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000254885.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000254936.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000254981.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000254981.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000254990.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000254990.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000254991.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000255031.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255031.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000255050.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255052.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000255100.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255142.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000255158.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000255165.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255234.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000255318.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000255320.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000255322.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000255326.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000255328.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000255337.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255343.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255366.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000255421.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255421.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000255434.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000255458.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255495.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000255565.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255621.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000255651.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000255669.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000255669.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000255670.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255717.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000255741.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000255847.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000255847.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000255966.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000255968.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000255992.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000256011.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000256050.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000256124.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000256146.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000256250.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000256312.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000256458.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000256576.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000256955.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000256967.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000256973.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000256982.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000257023.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000257139.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000257202.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000257221.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000257222.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000257270.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000257283.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000257285.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000257410.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000257433.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000257433.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000257449.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000257449.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000257496.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000257496.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000257496.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000257497.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000257534.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000257568.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000257613.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000257636.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000257718.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000257808.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000257809.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000257809.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000257894.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000257953.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000257964.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000257999.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258044.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000258086.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000258086.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258101.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000258101.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000258101.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000258122.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258136.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000258199.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258260.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000258260.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258285.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000258302.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000258303.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258317.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000258334.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000258378.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000258413.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000258428.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000258442.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000258443.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000258450.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000258455.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000258479.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258526.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258623.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000258654.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258658.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258675.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000258777.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000258789.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000258809.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000258819.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000258821.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000258858.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000258919.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000258920.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000258938.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000258942.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000258957.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259001.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259038.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000259048.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000259062.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000259081.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259088.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259146.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000259163.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259172.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000259172.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259198.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000259209.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000259212.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259230.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000259274.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259294.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000259298.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259341.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000259345.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000259366.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000259396.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259408.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259417.2 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000259424.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000259424.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259424.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000259439.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000259463.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000259475.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259520.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259520.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000259540.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000259540.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000259551.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259583.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259618.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000259628.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000259635.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259673.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000259673.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259694.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000259714.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259715.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259715.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000259727.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259744.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000259775.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259775.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000259783.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259783.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000259792.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000259799.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000259802.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000259806.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259806.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000259865.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000259891.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259901.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000259921.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000259933.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000259943.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000259946.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000259994.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260000.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000260011.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000260034.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000260038.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000260059.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000260083.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260100.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260100.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000260132.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000260141.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000260177.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260198.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260209.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000260257.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000260261.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260269.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000260273.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000260273.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260276.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260278.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260285.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260288.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260331.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260351.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260361.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260361.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000260372.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260411.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260411.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000260436.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000260447.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000260468.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000260475.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260495.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260528.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260536.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000260563.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260565.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000260572.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000260591.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000260592.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000260625.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260630.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000260643.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260643.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260645.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260645.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000260647.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260651.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000260693.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000260693.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260742.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000260743.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000260744.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000260757.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260787.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000260793.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260793.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000260796.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000260803.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000260808.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000260810.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000260823.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000260831.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000260841.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000260891.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000260905.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000260920.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000260936.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000260949.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260954.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000260976.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260978.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000260988.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000260997.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261002.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000261008.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000261008.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000261033.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000261039.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261043.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261051.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000261051.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000261064.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261064.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261114.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000261114.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261123.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261126.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261126.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261172.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000261189.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261195.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261204.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261204.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000261212.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261242.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261251.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261252.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261252.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261270.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000261270.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261270.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000261280.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000261286.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000261295.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261302.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261305.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261338.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000261360.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261360.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261360.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000261366.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261366.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000261372.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000261404.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000261431.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000261433.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261451.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261451.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000261455.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000261474.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000261476.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000261481.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261513.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000261529.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261533.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261533.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000261534.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000261534.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000261534.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000261595.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261600.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000261616.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000261654.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000261673.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000261695.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000261744.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000261744.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000261766.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261775.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000261775.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261777.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000261798.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000261798.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261799.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261824.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000261879.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000261879.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261879.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000261886.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000261888.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000261971.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000262001.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000262098.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000262136.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000262147.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000262155.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000262171.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000262194.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000262213.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000262228.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000262298.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000262339.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000262339.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000262514.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000262668.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000262692.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000262810.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000262879.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000262879.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000263004.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000263004.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000263033.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000263050.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000263164.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000263214.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000263272.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000263293.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000263345.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000263412.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000263470.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000263603.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000263680.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000263862.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000263893.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000263916.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000264043.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000264107.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000264112.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000264125.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000264196.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000264222.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000264247.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000264270.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000264304.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000264339.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000264520.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000264546.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000264548.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000264608.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000264635.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000264635.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000264745.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000264769.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000264812.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000264812.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000264885.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000264940.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000264964.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000265206.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000265342.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000265349.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000265349.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000265394.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000265399.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000265413.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000265458.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000265479.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000265479.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000265490.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000265496.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000265791.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000265845.2 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000265908.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000265943.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000266126.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000266126.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000266261.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000266313.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000266401.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000266473.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000266473.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000266651.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000266717.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000266803.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000266821.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000266869.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000266904.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000266913.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000266921.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000266930.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000266947.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000266970.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000266978.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000266993.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000267010.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267018.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267034.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267064.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000267067.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267080.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267082.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000267093.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000267104.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267112.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267117.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267128.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000267130.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267138.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000267141.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267144.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267149.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267166.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267167.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267167.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267174.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267175.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000267219.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267230.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267249.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267249.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000267249.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000267272.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267272.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000267277.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267278.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267279.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000267284.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000267285.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267288.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000267288.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000267296.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000267298.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000267302.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267347.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267374.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000267388.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267390.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267395.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267395.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000267405.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000267414.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000267432.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267439.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000267462.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000267481.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267481.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000267505.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000267530.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000267546.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267547.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000267549.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000267560.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000267581.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267586.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267627.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267651.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267658.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267658.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000267672.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000267677.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000267702.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000267711.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000267730.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267745.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000267745.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000267751.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267759.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267778.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000267798.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000267852.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267852.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000267886.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000267904.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000267939.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000268006.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000268027.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000268049.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000268087.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000268157.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000268189.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000268205.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000268289.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000268362.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000268518.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000268518.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000268520.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000268564.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000268605.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000268613.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000268655.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000268686.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000268751.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000268945.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000268945.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000269038.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269044.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269054.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269161.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269161.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000269191.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000269194.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269202.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269220.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269246.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000269293.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269321.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269386.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269392.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269400.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269427.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269444.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000269463.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000269473.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000269483.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000269560.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000269609.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000269646.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000269652.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000269694.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269694.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269707.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269825.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000269834.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000269834.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000269843.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000269867.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000269892.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000269892.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269895.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269896.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269898.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269903.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269903.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000269911.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000269919.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000269925.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000269934.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269947.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000269947.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269947.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269949.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000269950.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000269959.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000269967.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000269979.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000269980.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269983.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000269983.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000269994.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000270006.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270019.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000270019.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270019.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000270020.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000270022.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000270030.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270039.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270041.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270049.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270052.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270062.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270068.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000270068.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000270083.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000270105.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270109.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000270115.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000270116.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000270116.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000270116.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000270127.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000270143.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000270165.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000270178.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000270189.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000270210.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000270362.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000270426.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000270726.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000270755.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000270933.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000271009.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000271032.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000271119.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000271127.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000271151.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000271228.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000271265.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000271334.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000271335.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000271367.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000271387.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000271420.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000271732.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000271755.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000271757.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000271762.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000271780.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000271789.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000271789.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000271843.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000271843.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000271851.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000271855.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000271856.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000271862.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000271912.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000271938.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000271948.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000271948.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000271964.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000271971.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000271978.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272002.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000272010.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000272048.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272070.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272077.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000272077.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272091.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272092.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000272097.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272112.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000272123.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000272128.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272142.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272148.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272156.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000272219.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272221.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000272221.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272226.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000272263.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000272275.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272308.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000272308.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000272346.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000272361.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272374.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272377.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000272382.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000272386.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272389.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272402.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272417.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000272455.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272457.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272505.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000272508.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272529.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000272562.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000272610.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272630.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000272631.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272660.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272677.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000272688.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272695.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000272696.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000272696.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272709.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272735.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000272764.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272769.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272777.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272791.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272808.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000272823.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272828.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272828.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000272849.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272862.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000272864.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000272864.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272872.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272885.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000272892.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000272895.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000272902.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272904.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000272913.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000272913.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000272914.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000272917.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000272949.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272950.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000272966.1 |
Predicted lncRNA |
Liver hepatocellular carcinoma |
|
| Motesanib |
ENSG00000272971.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000272979.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000273000.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273001.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000273006.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000273007.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000273011.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Motesanib |
ENSG00000273030.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000273032.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273035.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000273059.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000273071.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000273073.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000273097.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Motesanib |
ENSG00000273097.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000273113.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000273117.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000273137.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Motesanib |
ENSG00000273145.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000273148.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000273165.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000273165.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000273176.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000273183.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000273218.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273233.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273237.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000273249.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273257.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273265.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000273270.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000273289.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273295.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000273305.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Motesanib |
ENSG00000273308.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273311.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273313.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Motesanib |
ENSG00000273328.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Motesanib |
ENSG00000273335.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000273344.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273367.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000273368.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Motesanib |
ENSG00000273369.1 |
Predicted lncRNA |
Sarcoma |
|
| Motesanib |
ENSG00000273374.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Motesanib |
ENSG00000273381.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000273406.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Motesanib |
ENSG00000273437.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273454.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273473.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273481.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Motesanib |
ENSG00000273486.1 |
Predicted lncRNA |
Sarcoma |
|